In 2019, a team at the University of Washington launched a study that would eventually enroll over 580 middle-aged dogs across 45 states. They called it TRIAD — the Test of Rapamycin in Aging Dogs. The goal was simple: figure out if a drug already used in human transplant patients could slow down aging in dogs. Six years later, the first wave of results is in. And honestly? It is complicated.
I have been following this study since before it started. My colleague at UW, Dr. Matt Kaeberlein, has been talking about rapamycin and aging for over a decade. When he told me they were finally testing it on dogs, I was excited. When he told me the results, I was cautiously optimistic. And when I read the internet's reaction, I was frustrated. Because what people are saying online and what the data actually shows are two very different things.
What Is Rapamycin, and Why Dogs?
Rapamycin is an immunosuppressant originally discovered on Easter Island in the 1960s. It is used in humans to prevent organ transplant rejection. But in the early 2000s, researchers noticed something strange: when you give rapamycin to yeast, worms, and mice, they live longer. Not slightly longer. In some mouse studies, lifespan increased by 9 to 14 percent.
The mechanism targets something called mTOR — mechanistic Target of Rapamycin. Think of mTOR as a cellular growth accelerator. When it is active, cells build, divide, and grow. When you slow it down, cells shift into maintenance mode. They clean up damaged proteins, repair DNA, and basically do housekeeping. The theory is that constant growth and replication wears cells out. Periodic maintenance extends their useful life.
Dogs were the obvious next step. They age similarly to humans in many ways. They get cancer, heart disease, cognitive decline. They share our environment. And most importantly, dog owners actually care whether their dogs live longer. You can run a study and people will show up.
What the TRIAD Study Actually Found
Here is where I need to be precise, because precision matters with this stuff. The TRIAD study is a randomized, double-blind, placebo-controlled trial. That is the gold standard. Dogs were given either low-dose rapamycin or a placebo for 10 weeks, followed by a 52-week observation period.
The primary outcomes were safety and tolerability. Secondary outcomes included cardiac function, cognitive performance, and quality of life measures. The study was not designed to measure lifespan directly — that would take 10 to 15 years. Instead, it looked at biomarkers and functional improvements that predict longer, healthier lives.
| Outcome | Rapamycin Group | Placebo Group | Significance |
|---|---|---|---|
| Left ventricular mass reduction | -2.3% | +0.1% | Statistically significant |
| Diastolic function improvement | Moderate improvement | No change | Clinically meaningful |
| Cognitive test scores | Slight improvement | Decline in older dogs | Trending positive |
| Adverse events | Low (mild GI upset) | Similar | Well tolerated |
The cardiac data is what caught everyone's attention. Rapamycin reduced left ventricular mass — basically, it reversed some of the heart thickening that happens as dogs age. This is huge because heart disease is the second leading cause of death in dogs after cancer. A drug that keeps hearts younger for longer is not a small thing.
But — and this is the part that gets lost in the headlines — the cognitive data was mixed. Some older dogs showed slight improvements in memory tests. Others did not. The sample size for cognitive outcomes was smaller, and the testing methodology is still being refined. I would not tell anyone their 12-year-old dog is going to get sharper on rapamycin. The data does not support that yet.
What This Means for Your Dog Right Now
Nothing. That is the honest answer. Rapamycin is not FDA-approved for longevity in dogs. It is not available from your vet for this purpose. The doses used in TRIAD were carefully calculated and monitored by veterinary cardiologists. Giving your dog rapamycin on your own would be dangerous and irresponsible.
What the study does give us is proof of concept. Aging in dogs is not immutable. We can intervene. We can measure the effects. And we can do it safely, at least in the short term. The next phase of TRIAD is already underway — a longer study with more dogs, looking at harder endpoints like time to first major disease and overall survival.
The Internet Is Getting Ahead of Itself
I have seen Facebook groups where people are already sourcing rapamycin from compounding pharmacies and dosing their dogs based on mouse studies. This makes me angry. Mouse metabolism is not dog metabolism. The safety margins are different. The side effect profiles are different. And the TRIAD study used a specific formulation and monitoring protocol that your local pharmacy is not replicating.
One owner posted that her 9-year-old Golden Retriever was "aging in reverse" after three months on rapamycin. She had no blood work, no cardiac monitoring, and no control group. This is not science. This is hope dressed up as data. And hope is fine, but not when it puts dogs at risk.
Is rapamycin safe for all dog breeds?
The TRIAD study included a range of medium to large breeds. Small breeds were underrepresented. Brachycephalic breeds like Bulldogs and Pugs were excluded due to their existing cardiac risks. We do not know if rapamycin is safe for these dogs. We do not know if it is safe for dogs with kidney disease, liver disease, or cancer. The safety data applies to healthy, middle-aged dogs of specific sizes.
How long before rapamycin is available for dogs?
Realistically? Five to ten years, if the larger trials go well. The FDA approval process for veterinary drugs is slow. And longevity is not a recognized indication, which means regulators would need to create new frameworks. Some compounding pharmacies may offer it off-label sooner, but that comes with risks I would not take with my own dog.
Can I do anything now to slow my dog's aging?
Yes. The things that actually work are boring: keep your dog lean, exercise them appropriately, feed a balanced diet, maintain dental health, and stay current on preventive care. These interventions have decades of evidence. Rapamycin has one promising study. The boring stuff wins for now.
I will keep watching TRIAD. Scout is only five, so by the time rapamycin is a real option, she might be the right age to benefit. Until then, we are doing the boring stuff. Long walks. Good food. Regular checkups. And a lot of frisbee. Sometimes the best science is the kind you do not need a prescription for.
What would you do if a longevity drug for dogs became available tomorrow? Would you try it, or stick with what we know works?
